Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Answer about the linker

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Mar 09, 2021 2:11pm

90 Views

Post# 32754171

RE:RE:RE:RE:RE:Answer about the linker

All their pre-clinical data published up ti now was on mice.

Wino115 wrote: Interesting. The only thing I recall is in one of the recent conferences, Levesque or Marsolais let it slip out that the fast track was because of what the FDA saw in the preclinical work and when they spoke of animal testing, they used the term "tests in different animals" we did and it made me think they not only did small mice, but some other animals. Maybe they misspoke, but I definitely remember hearing that and thinking maybe rats, monkeys, etc... Perhaps part of the AACR presentation?

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity